Annemieke Willemze

Global Project Head, Efanesoctocog alfa (BIVV001), Rare Blood Disorders Development
Sanofi, Amsterdam, Netherlands

Presentation(s):

• LB 01.4 - Efficacy, Safety, and Pharmacokinetics of Once-Weekly Efanesoctocog Alfa (BIVV001) Prophylaxis in Previously Treated Patients With Severe Hemophilia A: Results From the Phase 3 XTEND-1 Study

  Sunday, July 10, 2022
  3:30 PM – 3:45 PM